This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension (SDHDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ib Abildgaard Jacobsen, Odense University Hospital
ClinicalTrials.gov Identifier:
NCT01062763
First received: February 3, 2010
Last updated: April 8, 2014
Last verified: April 2014
Results First Received: June 27, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Arterial Hypertension
Hypertension, Resistant to Conventional Therapy
Diabetes Mellitus
Interventions: Drug: spironolactone
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients recruited from outpatient clinics of endocrinology at two university hospitals and two general hospitals in the period from May 2010 to March 2012.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
163 patints screened. 44 screenfailures due to exclusion criteria as indicated. 119 randomized

Reporting Groups
  Description
Placebo 1tablet of matching placebo trated up to 2 if neccessary
Addition of Spironolactone

spironolactone is added to previous antihypertensive treatment

placebo : addition of placebo 1 to 2 tablets daily

spironolactone : 25 to 50 mg once daily


Participant Flow:   Overall Study
    Placebo   Addition of Spironolactone
STARTED   58 [1]   61 
COMPLETED   55   57 
NOT COMPLETED   3   4 
Adverse Event                3                4 
[1] 119 randomized.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Addition of Spironolactone

spironolactone is added to previous antihypertensive treatment

placebo : addition of placebo 1 to 2 tablets daily

spironolactone : 25 to 50 mg once daily

Placebo No text entered.
Total Total of all reporting groups

Baseline Measures
   Addition of Spironolactone   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 61   58   119 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   34   28   62 
>=65 years   27   30   57 
Age 
[Units: Years]
Mean (Standard Deviation)
 62.9  (7.1)   63.9  (6.9)   63.4  (6.9) 
Gender 
[Units: Participants]
     
Female   15   13   28 
Male   46   45   91 
Region of Enrollment 
[Units: Participants]
     
Denmark   61   58   119 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change of of Systolic Blood Pressure   [ Time Frame: 4 months ]

2.  Primary:   Change of Diastolic Blood Pressure   [ Time Frame: 4 months ]

3.  Secondary:   Adverse Effects   [ Time Frame: 4 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Ib A. Jacobsen
Organization: Dept. of Endocrinology, Odense University Hospital
phone: +45 27203135
e-mail: ib.abildgaard@rsyd.dk


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Ib Abildgaard Jacobsen, Odense University Hospital
ClinicalTrials.gov Identifier: NCT01062763     History of Changes
Other Study ID Numbers: EudraCT 2009-017033-22
2009-017033-22 ( EudraCT Number )
Study First Received: February 3, 2010
Results First Received: June 27, 2013
Last Updated: April 8, 2014